Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

about

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

Item

http://www.wikidata.org/entity/Q52641327

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

@en

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

@nl

type

Item

label

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

@en

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

@nl

prefLabel

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

@en

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

@nl

P1476

Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.

@en

P2093

Ailin Song

http://www.w3.org/2001/XMLSchema#string

Lingguang Mu

http://www.w3.org/2001/XMLSchema#string

Linhong Zhen

http://www.w3.org/2001/XMLSchema#string

Liyan Du

http://www.w3.org/2001/XMLSchema#string

Weiling Chen

http://www.w3.org/2001/XMLSchema#string

Xiaomei Li

http://www.w3.org/2001/XMLSchema#string

Yang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2

Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines

Breast metastases from a Renal Cell Carcinoma. A case report and review of the literature.

Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.

Thermal ablation therapies in patients with breast cancer liver metastases: a review.

Breast size and breast cancer: a systematic review.

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

Invasive ductal carcinoma of the breast with osteoclast-like giant cells and clear cell features: a case report of a novel finding and review of the literature.

[Squamous cell carcinoma of the breast: report of a case and review of the literature].

P304

7163-7169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MMR.2018.8769

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29568883

http://www.w3.org/2001/XMLSchema#string

P932

5928673

http://www.w3.org/2001/XMLSchema#string